Medicenna Therapeutics Corp MDNA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Medicenna Therapeutics Reports Second Quarter Fiscal 2027 Financial Results and Provides Corporate Update
Medicenna Reports More than Doubling of Median Overall Survival in Glioblastoma Patients With Unresectable Recurrent IDH-WT Tumors Following One Treatment with Bizaxofusp Versus a Matched External Control at SNO 2026
Medicenna Presents ABILITY-1 Data at SITC 2026 Showing 40% ORR in Gastrointestinal Cancer Patients with Biomarker Enriched Tumors Resistant to Approved Therapies
Medicenna Completes Phase 1/2 ABILITY-1 Enrollment and Announces Webinar to Discuss Updated MDNA11 Results with Key Opinion Leaders
Medicenna Reports Potent CD122 Blockade and Extended Survival with MDNA209 in Preclinical Models of Autoimmune Disease
Medicenna to Present Preclinical Data on Its CD122 Superantagonist MDNA209 at The Promises of Treg and Interleukin-2 Therapies Conference
Medicenna Announces Oral Presentation of Topline Data from the Phase 1/2 ABILITY-1 Study of MDNA11 at SITC 2026
Medicenna Announces Results of Annual General and Special Meeting of Shareholders
Trading Information
- Previous Close Price
- CA$0.18
- Day Range
- CA$0.18–0.22
- 52-Week Range
- CA$0.17–1.78
- Bid/Ask
- CA$0.21 / CA$0.22
- Shares Outstanding
- 92.30M
- Market Cap
- CA$20.31M
- Volume/Avg
- 463,991 / 61,575
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Medicenna Therapeutics Corp is the development and commercialization of IL-2, IL-4 and IL-13 Superkines and empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its platforms are Superkine, BISCUIT, TEMASK, Publications, and Scientific Publications.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 20
- Website
- https://www.medicenna.com
Valuation
Metric | MDNA |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 9.93 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
MDNA
Financial Strength
Metric | MDNA |
|---|---|
Quick Ratio | 1.11 |
Current Ratio | 1.25 |
Interest Coverage | — |
Quick Ratio
MDNA
Profitability
Metric | MDNA |
|---|---|
Return on Assets (Normalized) | −145.11% |
Return on Equity (Normalized) | −290.54% |
Return on Invested Capital (Normalized) | −290.00% |
Return on Assets
MDNA
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|zLDn!@ | LOCK|PY&C< | $136B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|q@m&?R# | LOCK|pY!Dy | $98B | |||
| Moderna Inc MRNA | LOCK|m#>?nLK | LOCK|&^d | $80B | |||
| argenx SE ADR ARGX | LOCK|#@##pz> | LOCK|p$ | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|!>b%WH | LOCK|vy | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|&##NGq?t | LOCK|>#?D | $31B | |||
| Incyte Corp INCY | LOCK|K?GwVZ | LOCK|!mj | $24B | |||
| BioNTech SE ADR BNTX | LOCK|JG$<!#^ | LOCK|^! | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|JWW?&Ns | LOCK|qS^^ | $20B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|&&<#MvY | LOCK|<C$ | $16B |